CRMD - CorMedix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
6.13
+0.07 (+1.16%)
At close: 4:00PM EST

6.13 0.00 (0.00%)
After hours: 4:15PM EST

Stock chart is not supported by your current browser
Previous Close6.06
Open6.04
Bid6.16 x 800
Ask6.17 x 1000
Day's Range6.04 - 6.30
52 Week Range4.86 - 13.70
Volume171,478
Avg. Volume250,782
Market Cap157.25M
Beta (3Y Monthly)3.02
PE Ratio (TTM)N/A
EPS (TTM)-1.57
Earnings DateNov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.50
  • Thomson Reuters StreetEvents

    Edited Transcript of CRMD earnings conference call or presentation 14-Nov-19 9:30pm GMT

    Q3 2019 CorMedix Inc Earnings Call

  • CorMedix (CRMD) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    CorMedix (CRMD) Reports Q3 Loss, Misses Revenue Estimates

    CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Nov. 14, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • GlobeNewswire

    CorMedix Inc. to Report Third Quarter 2019 Financial Results and Provide a Corporate Update on November 14

    BERKELEY HEIGHTS, N.J., Nov. 07, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
    Zacks

    CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

    CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    CorMedix Inc. Announces a Change to its Senior Leadership

    CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the Company and Robert Cook, the Chief Financial Officer of the Company, have mutually agreed not to renew his employment agreement, which expires on January 31, 2020. Mr. Cook will assist the Company in transitioning his responsibilities. Khoso Baluch, CorMedix Chief Executive Officer commented, “Bob joined the Company over two years ago, and we appreciate his contributions to CorMedix.

  • Have Insiders Been Buying CorMedix, Inc. (NYSEMKT:CRMD) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying CorMedix, Inc. (NYSEMKT:CRMD) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • GlobeNewswire

    CorMedix Completes Successful CMC Interaction with the FDA

    CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed its interaction with the FDA related to the chemistry, manufacturing and controls (CMC) package that will be needed to support Neutrolin’s new drug application (NDA). The FDA was supportive of Neutrolin’s proposed manufacturing program, including the active pharmaceutical ingredients (API), the container closure and testing, and indicated that it will conduct a thorough review of all of the CMC information as well as assess the commercial readiness of the various manufacturing facilities at the time of NDA filing.  No further CMC meetings with FDA are planned prior to NDA submission.

  • GlobeNewswire

    CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 26, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for.

  • GlobeNewswire

    CorMedix Inc. Announces Exercises of Outstanding Warrants

    The combination of this transaction, the completion of the Exchange Agreement with funds managed by Elliott Management Corporation earlier this month, and exercises and expirations since June 30, 2019 of warrants held by other investors has resulted in the Company receiving gross proceeds of approximately $10 million and reducing its warrant overhang by approximately 2.9 million shares.

  • GuruFocus.com

    Biggest Hedge Fund Buys of September

    Klarman, Paulson and Singer each reports a significant investment Continue reading...

  • Should You Worry About CorMedix, Inc.'s (NYSEMKT:CRMD) CEO Pay?
    Simply Wall St.

    Should You Worry About CorMedix, Inc.'s (NYSEMKT:CRMD) CEO Pay?

    In 2016 Khoso Baluch was appointed CEO of CorMedix, Inc. (NYSEMKT:CRMD). This report will, first, examine the CEO...

  • GlobeNewswire

    CorMedix Inc. to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    BERKELEY HEIGHTS, N.J., Sept. 03, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for.

  • Thomson Reuters StreetEvents

    Edited Transcript of CRMD earnings conference call or presentation 13-Aug-19 8:30pm GMT

    Q2 2019 CorMedix Inc Earnings Call

  • GlobeNewswire

    CorMedix Inc. Announces Exchange Agreement With Its Largest Investor

    In connection with the Exchange Agreement, Elliott has agreed to make a cash payment of $2 million and to exchange all of its outstanding warrants, 10% Senior Secured Convertible Notes (the principal and accrued interest of which would have amounted to a repayment obligation of approximately $10.1 million or been convertible into approximately 1.35 million shares if held to maturity), and Series C-2, Series D and Series F Convertible Preferred Stock for new Series G Convertible Preferred Stock.  The new Series G Convertible Preferred Stock is convertible into an aggregate of 5,560,138 shares of Common Stock, subject to a claw back of up to 139,769 shares of Common Stock, depending upon the occurrence of certain stock price-related conditions. Elliott is retaining the shares of Common Stock and Series E Preferred Stock that it currently holds.  With the completion of this exchange, the Company will have raised additional capital, will be debt-free and will have substantially reduced the amount of outstanding warrants as well as its classes of outstanding preferred stock.  A Special Committee of the Board of the Company, consisting of independent directors with no relationship to Elliott, after consulting with independent financial advisors, determined that the Exchange Agreement was in the best interests of the Company and recommended it to the Board for approval.

  • CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates

    CorMedix (CRMD) delivered earnings and revenue surprises of -9.09% and -73.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    CorMedix Inc. Reports Second Quarter and Six Month 2019 Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Aug. 13, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • Is CorMedix (NYSEMKT:CRMD) Weighed On By Its Debt Load?
    Simply Wall St.

    Is CorMedix (NYSEMKT:CRMD) Weighed On By Its Debt Load?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    CorMedix Inc. to Report Second Quarter 2019 Financial Results and Provide a Corporate Update on August 13

    BERKELEY HEIGHTS, N.J., Aug. 01, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • 7 A-Rated Stocks Under $10
    InvestorPlace

    7 A-Rated Stocks Under $10

    It's always hard to describe stocks that are trading under $10. Are they cheap stocks? Are they penny stocks? Are small-cap stocks bargains?Source: Shutterstock The fact is, a low-priced stock doesn't necessarily mean anything other than that it's low-priced. There's no reason to take a flyer on a low-priced stock just because it's low priced when a higher-priced stock (and few less shares) may get you a better stock.I do the same amount of leg work on every stock, regardless of its price. Then, once they've been through my Portfolio Grader system, I can parse that list by industry, momentum, fundamentals or in this case, price.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe seven A-rated stocks under $10 featured here have everything going for them, just like their higher-priced brethren. They just cost you a little less to get into. Or, you can take a bigger stake than you could in say a $30 stock. * The 10 Best Stocks to Invest in for August What's more, small-cap stocks (usually one and the same as low-priced stocks) are doing well now -- the Russell 2000 Index is the best indicator of the small caps, and it's up more than 14% year-to-date. And since they have been in the shadows while the big names get the glory, they're usually better values here as well. Orion Energy Systems (OESX)Orion Energy Systems Inc (NASDAQ:OESX) only has a market cap of $93 million. And while it had a pop in early 2017, it hasn't done much until recently.It's in the lighting business. Basically it designs, manufactures and installs commercial lighting systems and energy management solutions. That may not sound like a big business, but it depends on who your clients are.And recently it looks like OESX has landed a big client. Its stock is up 230% in the past 12 months and a whopping 477% YTD. And 100% in the past three months.It has landed a big fish to be sure. And if it's a big box retailer that's retrofitting its stores with energy-saving lighting, this is going to be a run that will last for a while.For now, however, few people are watching. Don't chase it, just buy in a little at a time. Sachem Capital Corp (SACH)Sachem Capital Corp (NYSE:SACH) is an interesting company. It's in the real estate investment trust (REIT) sector and is classified as a REIT. But it doesn't hold properties, its holds first mortgages on properties.It offers what's know in the business as "hard money loans", which are basically short-term (three years or less), secured non-banking loans for acquisition, renovation or development of properties in Connecticut, Massachusetts, New York and Rhode Island.It has about a $105 million market cap, and its performance has been solid. Year-to-date it's up 27%. And that should continue since both the REIT sector and the small cap sector are both doing well here. * 10 Small-Cap Stocks to Buy Before They Grow Up The real kicker is its 9.6% dividend. If you're looking for a long-term, small cap holding and a solid regional REIT play, look no further. New York Mortgage Trust (NYMT)New York Mortgage Trust (NASDAQ:NYMT) is another REIT, with all the benefits discussed earlier regarding being involved in two hot sectors at once.It also focuses on the mortgages and financial assets of a development or builder rather than the physical assets. With rates this low and likely headed lower, this is a very good time for a firm like NYMT since many developers will grab properties while rates are low and then can develop over time.In mid-July, the company offered an additional 20 million shares, which diluted current shareholders but has boosted its operating capital so it can make more deals while the market is hot.Its stock performance is about breakeven at this point, but it has a huge 13.1% dividend. Its $1.3 billion market cap also means it has aspirations to build a bigger company over time. Innovative Systems and Support (ISSC)Innovative Systems and Support Inc (NASDAQ:ISSC) has been building avionics and instrumentation for the airline industry since 1988. Its customers are a who's who of the major commercial airlines, logistics companies and governmental agencies.With a $94 million market cap, this is a niche player in the sector, but that simply means it's a reliable subcontractor to major contracts that are signed by various aviation companies. * 7 Strong Buy Stocks the Street Loves This has been a very good year for the company -- and its stock -- it's up 93% for the year and 150% YTD. With air travel expanding and online shopping continuing to grow, there's no doubt that airlines will be in need of the products ISSC delivers for many years to come. CorMedix (CRMD)CorMedix Inc (NASDAQ:CRMD) is a commercial-stage pharmaceutical company that focuses on its taurolidine technology to build a non-antibiotic, antimicrobial that can prevent bloodborne infections and inflammation in patients that are on IVs and catheters.It will be a contender with the long-time go-to, heparin.Earlier this month, the stock got a boost when the company announced that the Food and Drug Administration determined that it had passed its Phase III trial and doesn't need to expand its study further. That means CRMD is much closer to getting Neutrolin to market.It currently has a $219 million market cap and the stock has been doing well for a while. It's up 46% YTD and a whopping 214% in the past 12 months. CRMD has a good chance to be bought out or get a big licensing deal with a large pharmaceutical company. Adesto Technologies (IOTS)Adesto Technologies Corp (NASDAQ:IOTS) is a small chipmaker that specializes in non-volatile memory chips for the "Internet of Things" market.This is a massive long-term trend and as it expands, it's a great place for smaller chipmakers to grab a foothold. IOTS is a full stack IOT provider in the industrial, medical, consumer and communications sectors.The IOT semiconductor space is looking at a compounded annual growth rate (CAGR) of 25% until 2022 and CAGR of 35% for industrial IOT building blocks demand.It already works with the major players across its sectors and has a global presence. This means it will continue to grow with its partners. * 10 Companies I'd Love to See Go Public Right now, its market cap is a mere $247 million, but it's in a perfect position to grow alone or get acquired at a premium by a larger chip firm looking to gain market share in the sectors where IOTS thrives. Fluent (FLNT)Fluent Inc (NASDAQ:FLNT) is an online marketing platform for businesses and publishers.Remember, the old publishing model collapsed after the internet drove paper publishing into the ground. It also hit the direct mail business hard as well. Then, as everyone started filling your inbox with tons of junk mail, that became increasingly difficult as well.That left companies looking for ways to build their customer lists and create effective advertising that customers would see. And digital agencies like FLNT were born to market to and acquire customers.It has a $410 million market cap, so it has done well in the nine years since its founding and it continues to grow. Year-to-date it's up 54% and over the past 12 months it has returned 135%, yet still trades at a trailing P/E of 44.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy With Over 20% Upside From Current Levels * The 10 Best Stocks to Invest in for August * 6 Upcoming IPOs for August The post 7 A-Rated Stocks Under $10 appeared first on InvestorPlace.

  • GlobeNewswire

    CorMedix Presents at FDA Public Meeting on the Limited Population Pathway for Antibacterial and Antifungal Drugs

    BERKELEY HEIGHTS, N.J., July 17, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • Benzinga

    Why CorMedix Shares Are Rallying

    Shares of the micro-cap biotech CorMedix Inc. (NYSE: CRMD ) were advancing Tuesday following the announcement of positive FDA feedback on the company's lead investigational drug. What Happened The FDA's ...

  • GlobeNewswire

    CorMedix Receives Encouraging FDA Feedback on Neutrolin® LOCK-IT-100 Data

    BERKELEY HEIGHTS, N.J., July 09, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

  • GlobeNewswire

    CorMedix Announces Publication of Taurolidine Pre-Clinical Oncology Data in “Investigational New Drugs” Journal

    BERKELEY HEIGHTS, N.J., July 08, 2019 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.